dc.contributor.author | Bjelkarøy, Maria Torheim | |
dc.contributor.author | Simonsen, Tone Breines | |
dc.contributor.author | Siddiqui, Tahreem Ghazal | |
dc.contributor.author | Cheng, Socheat | |
dc.contributor.author | Grambaite, Ramune | |
dc.contributor.author | Saltyte Benth, Jurate | |
dc.contributor.author | Lundqvist, Anders Christofer | |
dc.date.accessioned | 2024-07-24T06:05:57Z | |
dc.date.available | 2024-07-24T06:05:57Z | |
dc.date.created | 2024-02-22T07:49:52Z | |
dc.date.issued | 2024 | |
dc.identifier.citation | BMJ Open 2024;14 | en_US |
dc.identifier.issn | 2044-6055 | |
dc.identifier.uri | https://hdl.handle.net/11250/3142988 | |
dc.description.abstract | Objectives Disease and medication use in older age is a consequence of age-related declining health. Multimorbidity followed by polypharmacy is common. Central nervous system depressing (CNSD) drugs such as opioids, benzodiazepines and z-hypnotics are not recommended for long-term use in older adults but are in use by many. We aimed to assess mortality and change in health-related quality of life (HRQoL) in older adults with long-term use of CNSDs.
Method A prospective observational study was conducted at Akershus University Hospital, Norway, 2017–2019, with follow-up in 2021–2022, including 246 participants aged 65–90. At 5-year follow-up, 78 (32%) participants had passed away. Mortality data were collected from patient electronic health records. Of the surviving 168 (68%), we collected further follow-up data from 38 (16%) participants. Follow-up included demographic and clinical data. The EuroQuol Group EQ-5D-5L questionnaire was used to measure HRQoL. Analysis include Cox regression model for survival data and linear mixed model for change in HRQoL over time.
Results At follow-up, 78 (31.7%) were deceased. Mean survival time was 3.3 years. Total time for survival data was 4.7 years. Mortality was higher among participants with long-term use of CNSD (HR 1.9 95% CI (1.2 to 3.2), p=0.01). The multivariable analysis found being older (HR 1.1 95% CI (1.0 to 1.1), p=0.020) and male sex (HR 2.1 95% CI (1.2 to 3.5), p=0.008) to be associated with increased risk of mortality. According to the linear mixed model (n=38), there was no significant difference between surviving users and non-users in change in HRQoL EQ-5D-5L index from baseline to follow-up.
Conclusion Mortality was higher for long-term users of CNSDs at 5-year follow-up. Being older and male sex were associated with mortality. Among survivors, there was no significant difference between the groups in change of HRQoL over time. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | BMJ | en_US |
dc.rights | Navngivelse-Ikkekommersiell 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/deed.no | * |
dc.title | Mortality and health-related quality of life in older adults with long-term use of opioids, z-hypnotics or benzodiazepines: a prospective observational study at 5 years follow-up | en_US |
dc.title.alternative | Mortality and health-related quality of life in older adults with long-term use of opioids, z-hypnotics or benzodiazepines: a prospective observational study at 5 years follow-up | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.volume | 14 | en_US |
dc.source.journal | BMJ Open | en_US |
dc.source.issue | 2 | en_US |
dc.identifier.doi | 10.1136/bmjopen-2023-079347 | |
dc.identifier.cristin | 2248674 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |